Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Akebia Therapeutics, Inc. AKBA

Set alert

Price alert · AKBA

All alert types
0.74 USD +0.03 +3.90%

As of Nov 3, 11:35 AM ET

Bid
0.73 × 1
Ask
0.74 × 7
0.71 Day range 0.7474
0.542 52-week range 2.15
YTD
-54.29%
1 year
-65.28%
Open
0.7247
Prev close
0.7084
Mkt cap
204.01M
Vol
1.74M
Avg vol
7.88M
EPS
-0.12
P/E
0.00
Div yield
0.00%
More statistics
Low
0.71
High
0.7474
Forward P/E
-7.15
Beta
0.73
Short ratio
4.71
Inst. own
27.33%
Dividend
0.00
Ex-div date
50-d avg
1.80
200-d avg
1.45
1y target
5.50

MAX chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Sep 6, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (40)
NameDateAgo
SMA: BearishNov 1, 20251 year ago
MACD: Sell SignalNov 1, 20251 year ago
SMA: BearishOct 1, 20251 year ago
SMA: BullishOct 1, 20242 years ago
SMA: BearishSep 1, 20242 years ago
SMA: BullishJul 1, 20242 years ago
SMA: BearishApr 1, 20242 years ago
SMA: BullishDec 1, 20232 years ago
SMA: BullishNov 1, 20233 years ago
SMA: BearishOct 1, 20233 years ago
SMA: BearishAug 1, 20233 years ago
SMA: BullishJul 1, 20233 years ago
SMA: BullishDec 1, 20223 years ago
MACD: Buy SignalOct 1, 20224 years ago
SMA: BearishJul 1, 20215 years ago
SMA: BullishJun 1, 20215 years ago
MACD: Sell SignalOct 1, 20206 years ago
SMA: BearishSep 1, 20206 years ago
SMA: BearishSep 1, 20206 years ago
SMA: BearishMar 1, 20206 years ago

Newest 20 of 40.

Analyst view

Price target (mean) 5.50 +647.3% upside
Target (low)
4.00
Target (mean)
5.50
Target (high)
7.50
Ratings (0m) 3 3 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 3
  • 1 month ago 3
  • 2 months ago 3

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

AKBA analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.04-0.04 – -0.040.000.0%40.91M-27.2%1
Next quarter-0.075-0.15 – 0.00-0.0843+11.0%35.61M+9.2%2
Current year-0.26-0.26 – -0.26-0.2732+4.8%154.60M-20.6%1
Next year-0.195-0.47 – 0.08-0.26+25.0%177.96M+15.1%2

Upgrades and downgrades

The latest rating changes

AKBA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 23, 2024HC Wainwright & Co.ReiteratedBuyBuy
Oct 10, 2024HC Wainwright & Co.ReiteratedBuyBuy
Oct 8, 2024HC Wainwright & Co.ReiteratedBuyBuy
Sep 6, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 12, 2024HC Wainwright & Co.MaintainedBuyBuy
Mar 28, 2024HC Wainwright & Co.MaintainedBuyBuy
Mar 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
Nov 17, 2023HC Wainwright & Co.MaintainedBuyBuy
Sep 27, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 28, 2023HC Wainwright & Co.UpgradeNeutralBuy
Aug 11, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
Jun 21, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
Jun 14, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
Jun 2, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
May 31, 2023Piper SandlerUpgradeNeutralOverweight
May 30, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
May 26, 2023HC Wainwright & Co.ReiteratedNeutralNeutral
May 9, 2023NeedhamReiterated—Neutral
Apr 26, 2023HC Wainwright & Co.Maintained—Neutral
Mar 31, 2023HC Wainwright & Co.Reiterated—Neutral
Mar 10, 2023HC Wainwright & Co.Reiterated—Neutral
Feb 22, 2023HC Wainwright & Co.Maintained—Neutral
May 16, 2022HC Wainwright & Co.Maintained—Neutral
Mar 31, 2022HC Wainwright & Co.DowngradeBuyNeutral
Mar 31, 2022NeedhamDowngradeBuyHold
Mar 31, 2022MizuhoDowngradeBuyNeutral
Mar 31, 2022Piper SandlerDowngradeOverweightNeutral
Nov 11, 2021HC Wainwright & Co.Maintained—Buy
Mar 8, 2021Cantor FitzgeraldInitiated—Overweight
Mar 8, 2021HC Wainwright & Co.Maintained—Buy